Inicio/Acciones/XCUR

XCUR

USD

Exicure Inc. Common Stock

$10.800-0.632 (-5.526%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$11.432

Máximo

$11.607

Mínimo

$10.800

Volumen

0.00M

Fundamentos de la Empresa

Capitalización de Mercado

70.3M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.03M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $1.44Actual $10.800Máximo $36

Noticias Relacionadas

14 abr 2025 · 22:11

BusinessWire

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure, Inc. (NASDAQ:XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

11 abr 2025 · 23:42

BusinessWire

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. (NASDAQ:XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid Leukemia (AML) with